Results 41 to 50 of about 16,542 (247)

Dupilumab facial redness: Histologic characterization on a series of four cases

, 2022
Dupilumab-related head and neck dermatitis is an increasingly reported clinical manifestation occurring in 4-10% of patients on dupilumab that was apparently not reported in clinical trials.
Muharremi R., Dybala A., Carnicelli G., Grieco T., Sernicola A., Gomes V.   +5 more
core   +2 more sources

Real-world treatment patterns in patients with chronic rhinosinusitis with nasal polyps who initiated dupilumab: A US claims analysis

Journal of Allergy and Clinical Immunology: Global
Background: Dupilumab was approved as an add-on maintenance treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps based on the pivotal phase 3 trials.
Jayant M. Pinto, MD, Mirko Fillbrunn, PhD, Bruno Martins, PhD, Min Yang, PhD, Chao Chen, PhD, Scott Nash, MD, Mark Corbett, MD, Aakash Gandhi, PhD, Zhixiao Wang, PhD   +8 more
doaj   +1 more source

Tumors in the setting of dupilumab use: A review of the literature

World Allergy Organization Journal
Dupilumab is the first monoclonal antibody approved for treating moderate-to-severe atopic dermatitis (AD) and has significantly improved the quality of life of AD patients.
Shumeng Guo, Liangchun Wang, MD, PhD, Dingfang Bu, MD, PhD, Fengjie Liu, MD, PhD   +3 more
doaj   +1 more source

How Can Dupilumab Cause Eosinophilic Pneumonia?

Biomolecules, 2022
Reports of eosinophilic pneumonia (EP) as a side effect of dupilumab administration are limited in previous studies. Herein, we report two cases in which EP developed subsequent to the administration of dupilumab for eosinophilic chronic rhinosinusitis ...
Momoko Kurihara, Katsunori Masaki, Emiko Matsuyama, Masato Fujioka, Reina Hayashi, Saki Tomiyasu, Kotaro Sasahara, Keeya Sunata, Masato Asaoka, Yuto Akiyama, Miyuki Nishie, Misato Irie, Takae Tanosaki, Hiroki Kabata, Koichi Fukunaga   +14 more
doaj   +1 more source

Biologics Adoption in CRSwNP and the Associated Decline in Endoscopic Sinus Surgery: A Longitudinal Claims Database Study

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Biologic treatments were introduced for chronic rhinosinusitis with nasal polyps (CRSwNP) in 2019. Treatment algorithms for medically refractory CRSwNP remain open, with patients choosing among surgery, biologics, or both. Real‐world utilization of surgery and biologics remains incompletely characterized.
Stephanie Shintani Smith, Sam L. Kaefer, Harsh Duvvuru, Robert C. Kern, Brent A. Senior, Vijay R. Ramakrishnan   +5 more
wiley   +1 more source

Feasibility of continued treatment with dupilumab in patients with type 2 inflammatory disease who developed eosinophilic pneumonia: 3 case reports

Respirology Case Reports
Several reports have described dupilumab‐induced eosinophilic pneumonia (EP) after treatment with dupilumab in patients with type 2 inflammatory disease. Other reports have suggested the efficacy of dupilumab for chronic EP (CEP).
Masamitsu Hamakawa, Ayaka Tanaka, Fumiaki Tokioka, Tadashi Ishida   +3 more
doaj   +1 more source

Hypereosinophilic Dermatitis: Successful Treatment with Dupilumab

, 2023
Chenyu Wu, Jianzhong Zhang, Yan Zhao Department of Dermatology, People’s Hospital of Peking University, Beijing, People’s Republic of ChinaCorrespondence: Yan Zhao, Email 13311373780@163.comAbstract: Hypereosinophilic dermatitis (HED) is a subtype of ...
Zhang J, Wu C, Zhao Y
core  

Incidence of Conjunctivitis and Keratitis Among Individuals with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab in the United States: a Cohort Study in Routine Care Based on Healthcare Claims

Dermatology and Therapy
Introduction In clinical trials of patients with atopic dermatitis (AD), conjunctivitis and keratitis occurred more frequently with dupilumab than placebo.
Jessica M. Franklin, Andrea F. Marcus, Ihtisham Sultan, Ashley Howell, Sarah-Jo Sinnott, Jeannette Green, Stephen Ezzy, Robert Gately, Rachel E. Sobel, Florence T. Wang   +9 more
doaj   +1 more source

Allergen immunotherapy and dupilumab in atopic dermatitis: Clinical efficacy and disparities in immunological indicators

World Allergy Organization Journal
Objective: Allergen immunotherapy (AIT) and dupilumab have been confirmed to improve symptoms of atopic dermatitis (AD); however, the precise immune mechanisms underlying their efficacy and whether they can elicit synergistic immune effects remain not ...
Jin Liu, MM, Lin Yang, MD, PhD, Qingxiu Xu, MD, Qing Jiang, PhD, Nan Huang, MD, Wenjing Li, PhD, Yaqi Yang, MD, Dongxia Ma, MD, Le Li, MM, Yangxue Fu, PhD, Hao Chen, PhD, Rongfei Zhu, MD, PhD   +11 more
doaj   +1 more source

The synergistic impact of granulocytic myeloid‐derived suppressor cells and innate lymphoid cells in systemic sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by immune dysregulation and fibrosis, with myeloid‐derived suppressor cells (MDSCs) emerging as important regulators of immune responses. However, the role of MDSCs in SSc‐associated fibrosis and their interactions with other immune cell populations remain poorly ...
Stefanie Weber, Mario R. Angeli, Hashem Mohammadian, Hannah Labinsky, Maria Gabriella Raimondo, Richard Demmler, Yuko Ariza, Thomas Wohlfahrt, Markus Luber, Yi‐Nan Li, Jörg H.W. Distler, Tobias Bäuerle, Georg Schett, Simon Rauber, Andreas Ramming, Alina M. Ramming   +15 more
wiley   +1 more source